Recent studies have revealed that ARID1A, encoding AT-rich interactive domain 1A (SWI-like), is frequently mutated across a variety of human cancers and also has bona fide tumor suppressor properties. Consequently, identification of vulnerabilities conferred by ARID1A mutation would have major relevance for human cancer. Here, using a broad screening approach, we identify ARID1B, an ARID1A homolog whose gene product is mutually exclusive with ARID1A in SWI/SNF complexes, as the number 1 gene preferentially required for the survival of ARID1A-mutant cancer cell lines. We show that loss of ARID1B in ARID1A-deficient backgrounds destabilizes SWI/SNF and impairs proliferation in both cancer cells and primary cells. We also find that ARID1A and ARID1B are frequently co-mutated in cancer but that ARID1A-deficient cancers retain at least one functional ARID1B allele. These results suggest that loss of ARID1A and ARID1B alleles cooperatively promotes cancer formation but also results in a unique functional dependence. The results further identify ARID1B as a potential therapeutic target for ARID1A-mutant cancers.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Cheung, H.W. et al. Proc. Natl. Acad. Sci. USA 108, 12372–12377 (2011).
Shao, D.D. et al. Genome Res. 23, 665–678 (2013).
Wu, J.N. & Roberts, C.W. Cancer Discov. 3, 35–43 (2013).
Ryme, J., Asp, P., Bohm, S., Cavellan, E. & Farrants, A.K. J. Cell. Biochem. 108, 565–576 (2009).
Tolstorukov, M.Y. et al. Proc. Natl. Acad. Sci. USA 110, 10165–10170 (2013).
Klochendler-Yeivin, A. et al. EMBO Rep. 1, 500–506 (2000).
Bultman, S. et al. Mol. Cell 6, 1287–1295 (2000).
Kim, J.K. et al. Mol. Cell. Biol. 21, 7787–7795 (2001).
Roberts, C.W., Leroux, M.M., Fleming, M.D. & Orkin, S.H. Cancer Cell 2, 415–425 (2002).
Gao, X. et al. Proc. Natl. Acad. Sci. USA 105, 6656–6661 (2008).
Sausen, M. et al. Nat. Genet. 45, 12–17 (2013).
Barretina, J. et al. Nature 483, 603–607 (2012).
Cerami, E. et al. Cancer Discov. 2, 401–404 (2012).
Wang, X. et al. Cancer Res. 69, 8094–8101 (2009).
Oike, T. et al. Cancer Res. 73, 5508–5518 (2013).
Filippakopoulos, P. et al. Nature 468, 1067–1073 (2010).
Oltersdorf, T. et al. Nature 435, 677–681 (2005).
Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A. & Shokat, K.M. Nature 503, 548–551 (2013).
Li, X.S., Trojer, P., Matsumura, T., Treisman, J.E. & Tanese, N. Mol. Cell. Biol. 30, 1673–1688 (2010).
Kim, W. et al. Nat. Chem. Biol. 9, 643–650 (2013).
Isakoff, M.S. et al. Proc. Natl. Acad. Sci. USA 102, 17745–17750 (2005).
We thank Ping Lu for technical assistance with the setup of the sucrose sedimentation assay. X.W. was supported by a post-doctoral fellowship from David Abraham Foundation and Rally Foundation and a research grant from St. Baldrick's Foundation. B.G.W. was supported by a Childhood Cancer Research Grant from the Pablove Foundation. Z.W. is supported by US National Institutes of Health grant R01HL109054. This work was supported by US National Institutes of Health grants R01CA172152 (C.W.M.R.) and R01CA113794 (C.W.M.R.) and a U01 NCI Mouse Models of Cancer Consortium Award (C.W.M.R.). The Garrett B. Smith Foundation, Miles for Mary and the Cure AT/RT Now foundation (C.W.M.R.) provided additional support.
The authors declare no competing financial interests.
About this article
Cite this article
Helming, K., Wang, X., Wilson, B. et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 20, 251–254 (2014). https://doi.org/10.1038/nm.3480
Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Gastric Cancer (2021)
Expert Opinion on Drug Discovery (2021)
International Journal of Molecular Sciences (2021)
Cellular Oncology (2021)